EGFR and lung cancer: In other types of lung cancer with epidermal growth factor receptor (EGFR) mutations, commonly tyrosine kinase inhibitors (TKi) against the mutant EGFR or anti-EFGR antibodies are applied alone or in new combination therapy trials with other anti-cancer therapeutics [17].